Drug intelligence / Profile preview

AZD8931 + anastrozole

Development stage: Discontinued
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AZD8931 + anastrozole is a combination therapy consisting of AZD8931, an orally bioavailable, reversible tyrosine kinase inhibitor of EGFR, HER2, and HER3 signaling, and anastrozole, an aromatase inhibitor. This combination was investigated to determine if adding AZD8931 to endocrine therapy would delay the development of endocrine resistance in patients with hormone-sensitive advanced breast cancer.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)CYP19A1 (Aromatase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on AZD8931 + anastrozole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD8931 + anastrozole.

Explore the full profile